⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5858264 | 0.74 | — | — | |
| SCHEMBL14603669 | 0.69 | — | — | |
| SCHEMBL4561805 | 0.64 | SIGMAR1 (0.54) | — | |
| SCHEMBL15156228 | 0.64 | SIGMAR1 (0.54) | — | |
| SCHEMBL29383086 | 0.64 | SIGMAR1 (0.54) | — | |
| SCHEMBL29005371 | 0.63 | PDK1 (0.31) | — | |
| SCHEMBL7488660 | 0.61 | — | — | |
| SCHEMBL4918593 | 0.61 | — | — | |
| SCHEMBL19153220 | 0.60 | PIK3CD (0.32) | — | |
| SCHEMBL31647978 | 0.59 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11999802-B2 | Compositions and methods for selective protein degradation | NOVARTIS AG (CH) | 2024-06-04 | — | — | US | disclosed |
| US-11753418-B2 | Compounds for the modulation of Myc activity | SYROS PHARMACEUTICALS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230174933-A1 | METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS | NOVARTIS AG (CH) | 2023-06-08 | — | — | US | disclosed |
| US-20230144106-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | SYROS PHARMACEUTICALS INC (US) | 2023-05-11 | — | — | US | disclosed |
| EP-4110377-A2 | METHODS OF MAKING CHIMERIC ANTIGEN RECEPTOR-EXPRESSING CELLS | Novartis AG (CH) | 2023-01-04 | — | — | EP | disclosed |
| CN-115397460-A | Methods of making cells expressing chimeric antigen receptors | 诺华股份有限公司 | 2022-11-25 | — | — | CN | disclosed |
| US-11274103-B2 | Compounds for the modulation of MYC activity | SYROS PHARMACEUTICALS, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| US-20220048927-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2022-02-17 | — | — | US | disclosed |
| US-11124527-B2 | Compounds for the modulation of Myc activity | SYROS PHARMACEUTICALS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210221820-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | SYROS PHARMACEUTICALS INC (US) | 2021-07-22 | — | — | US | disclosed |
| US-20190048019-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2019-02-14 | — | — | US | disclosed |
| US-20180354972-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-12-13 | — | — | US | disclosed |
| US-20180162851-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-06-14 | — | — | US | disclosed |
| WO-2016196910-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | SYROS PHARMACEUTICALS, INC. (US) | 2016-12-08 | — | — | WO | disclosed |
| WO-2016197078-A1 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | SYROS PHARMACEUTICALS, INC. (US) | 2016-12-08 | — | — | WO | disclosed |
| EP-1065206-B1 | Tetrazolylalkyl indole compounds as anti-inflammatory and analgesic agents | PFIZER (US) | 2002-10-09 | — | — | EP | disclosed |
| EP-1065204-B1 | Bicycliccarbonyl indole compounds as anti-inflammatory/analgesic agents and as COX-2 inhibitors | PFIZER (US) | 2002-04-10 | — | — | EP | disclosed |
| US-6303628-B1 | FOR THE TREATMENT OF A MEDICAL CONDITION IN WHICH PROSTAGLANDINS ARE IMPLICATED AS PATHOGENS IN MAMMALS | PFIZER INC | 2001-10-16 | — | — | US | disclosed |
| EP-1065204-A1 | Bicycliccarbonyl indole compounds as anti-inflammatory/analgesic agents and as COX-2 inhibitors | PFIZER INC. (US) | 2001-01-03 | — | — | EP | disclosed |
| EP-1065206-A1 | Tetrazolylalkyl indole compounds as anti-inflammatory and analgesic agents | PFIZER INC. (US) | 2001-01-03 | — | — | EP | disclosed |